Neuromedin U Induces Activation of Peripheral Group 2 Innate Lymphoid Cells through the ERK Pathway in Allergic Rhinitis Patients

Abstract

<b><i>Introduction:</i></b> In allergic diseases, group 2 innate lymphoid cells (ILC2s) play critical roles. Neuromedin U (NMU), a highly conserved multifunctional neuropeptide, is secreted by cholinergic neurons and involved in asthma pathogenesis by amplifying lung inflammation driven by ILC2s. However, the precise effects of NMU on ILC2s in allergic rhinitis (AR) and related diseases remain unclear. <b><i>Methods:</i></b> A total of 15 patients with persistent AR and 8 healthy controls (HCs) were enrolled in the study. Visual analog scale (VAS) scores are used to assess the severity of clinical symptoms in AR patients. The percentages of ILC2s in peripheral blood mononuclear cells (PBMCs) were enumerated using flow cytometry. The soluble or intracellular cytokines (IL-5 and IL-13) in PBMCs or sorted ILC2s were assessed in response to various stimuli with IL-33, NMU, IL-33 combined with extracellular signal-related kinase (ERK) inhibitor or NMU combined with ERK inhibitor in the presence of IL-2. <b><i>Results:</i></b> We confirmed the proportion of circulating ILC2s was significantly higher in AR patients than in HCs. ILC2s levels were found to be positively related to VAS scores. We also discovered that the release of IL-5 and IL-13 in AR patients’ PBMCs stimulated by NMU (<i>p</i> < 0.0001 and <i>p</i> < 0.0001, respectively) or IL-33 (<i>p</i> = 0.002; <i>p</i> = 0.044, respectively) was significantly higher than in HCs. In AR patients, NMU stimulated PBMCs or ILC2s to generate greater inflammatory factors IL-5 and IL-13 compared to IL-33. Furthermore, we observed that NMU-promoted ILC2s activation and proliferation functions were restricted when the ERK pathway was inhibited. <b><i>Conclusion:</i></b> NMU effectively activated ILC2s in AR patients to produce Th2-type cytokines, and this activation can be prevented by ERK pathway inhibitors. Our findings shed new light on the neuro-immune mechanism of AR and offer new insights into its prevention and treatment.

Neuroimmune communication in allergic rhinitis

“…NMU cooperatively enhanced IL-5 and IL-13 expression through IL-33-dependent or IL-33-independent mechanisms ( 96 , 98 ). A recent study in AR patients demonstrated that NMU activates ILC2s, resulting in the upregulation of the inflammatory factors IL-5 and IL-13 rather than IL-33 in patients with AR, triggering a type 2 inflammatory response, which was inhibited upon ERK pathway blockade ( 99 ).…”